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Background: Patients with severe chronic airway obstruction might suffer danger-
ous hypoxemia after administration of a b-agonist despite bronchodilation.
Methods: We first compared the acute effects on gas exchange of two doses of
formoterol Turbuhaler (9 and 18 mg) in 10 patients with acute exacerbation of COPD.
Afterwards, we compared the acute effects of formoterol Turbuhaler 9mg with those
of formoterol/budesonide combination in a single inhaler (Turbuhaler) 9/320 mg in 10
other patients with acute exacerbation of COPD. Finally, we compared the changes
in PaO2 induced by formoterol Turbuhaler 9 mg or formoterol/budesonide combina-
tion in a single inhaler (Turbuhaler) 9/320 mg with those in FEV1 in 10 other patients
with acute exacerbation of COPD. Each agent was given on separate days, and the
patients’ arterial blood gases were measured at baseline and at intervals of 120min.
Results: Small but statistically significant declines in PaO2 were found after
administration of both formoterol 9 and 18 mg. In the second group of patients,
formoterol 9 mg alone again induced a significant decrease in PaO2. However, the
simultaneous administration of budesonide 320 mg significantly reduced the
acute effect of formoterol on PaO2. In a third group of 10 patients we confirmed a
small but significant decrease in PaO2 after formoterol alone and the reduction of
this effect when budesonide was administered simultaneously. Moreover, we also
documented that addition of budesonide amplified the fast onset of action of
formoterol.
Conclusions: These results suggest that when treating patients suffering from acute
exacerbation of COPD with formoterol, it is prudent to check their arterial bloodElsevier Ltd. All rights reserved.
o Margherita 24, 80121 Napoli, Italy. Tel.: +39 081 747 3334; fax: +39 081 404 188.
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the potential for acute effects of formoterol on blood-gas tensions.
& 2005 Elsevier Ltd. All rights reserved.Introduction
In most patients with acute exacerbations of COPD,
there appears to be a component of the worsened
airflow obstruction that is particularly responsive to
bronchodilators.1 Therefore, when airway obstruc-
tion increases, the therapeutic option is to add a
short-acting inhaled b2 agonist, for a rapid relief of
bronchospasm.2 Obviously, this bronchodilator
should be titrated to maximal effect when possible,
monitoring closely for adverse effects of the larger-
than-usual doses that are sometimes necessary to
relieve airway obstruction.
Recently, we have suggested long-acting b2
agonists, formoterol and salmeterol, as potential
option in the treatment of acute exacerbations of
COPD,3 although these agents are currently not
approved for use in this pathologic condition
because they must be intended for maintenance
treatment and not immediate symptomatic relief.
This opinion was supported by results of several
small clinical trials.4–8 In particular, in a selected
group of patients with mild acute exacerbations of
COPD, formoterol via Turbuhaler induced a fast
bronchodilation that was dose dependent and not
significantly different from that caused by salbuta-
mol.5 In general, a delivered dose of 18-mg
formoterol seemed to induce clinically relevant
effect in many patients suffering from acute
exacerbation of COPD.4,5 Interestingly, formoterol
did not induce significant modifications in SpO2 in
these patients. However, some subjects presented
a decrease in SpO2 under 90%.
5,7,8
This finding was not a real surprise because the
administration of b-adrenergic agents to patients
with airways obstruction often results in a transient
decrease in PaO2 despite concomitant bronchodila-
tion.9 This has been attributed to the pulmonary
vasodilator action of these agents, increasing blood
flow to poorly ventilated lung regions and thus
increasing ventilation–perfusion inequality, a
shunt-like effect.10,11
Since this effect could be potentially dangerous
for patients suffering from acute exacerbation of
COPD and hypoxemia, we aimed to investigate the
acute effects of formoterol inhalation on the
arterial blood gas tensions of hospitalized patients
with acute exacerbation of COPD. We also investi-
gated the influence of the acute addition of
budesonide on the acute effects of formoterol inthis type of patients in view of the documented
capacity of budesonide to influence the effects of
formoterol,12 and the possibility of treating pa-
tients with acute exacerbations of COPD with this
inhaled corticosteroid.13,14Patients and methods
Study population
Thirty patients admitted to our Unit were recruited
on the basis of having an exacerbation of COPD
requiring hospitalization, an age of more than 50
years, a smoking history of more than 20-pack
years, an FEV1 of less than 70% predicted for age
and height, a PaO2 of less than 70mmHg. The
presence of a COPD exacerbation was diagnosed
when physician observed a sustained worsening of
the patient’s condition, from the stable state and
beyond normal day-to-day variations, necessitating
a change in regular medication in a patient with
underlying COPD.15 Exacerbations were considered
severe because patient/physician recognised ob-
vious and/or rapid deterioration in condition,
requiring hospitalisation.15 The exclusion criteria
were: personal or family history of asthma, atopy,
allergic disease, presence of eosinophilia, use of
systemic steroids within the preceding month,
presence of severe hypertension, or uncontrolled
(or difficult to control) diabetes mellitus, or if a
specific cause for the exacerbation, such as
pneumonia, pneumothorax, or heart failure, was
diagnosed. Patients were also excluded if they
were at risk of imminent acute respiratory failure
requiring mechanical ventilation or admission to
the intensive care unit (pH o7.30 and/or Pa-
CO2470mmHg, and/or PaO2o50 mmHg despite
supplemental oxygen). The study was approved by
the ethics committee and all patients gave written
informed consent.Study protocol
This was a three-step study. In the first step, 10
patients received formoterol Turbuhaler 9 mg (1
inhalation)+placebo (1 inhalation) or formoterol
Turbuhaler 18 mg (2 inhalations) in 2 consecutive
days under randomized, cross-over, double-blind
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Figure 1 Mean changes (7SE) in PaO2 and PaCO2 with
time after administration of two different doses of
formoterol (9 and 18 mg) via Turbuhaler (step 1).
Po0:05, Po0:01, Po0:001 vs. baseline.
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patients (10 for each step) received formoterol
Turbuhaler 9 mg (1 inhalation)+placebo (1 inhala-
tion) or formoterol 9 mg+budesonide 320 mg in a
single Turbuhaler (2 inhalations of 4.5/160-mg) in 2
consecutive days, always under randomized, cross-
over, double-blind conditions.
Oral bronchodilators were not permitted during
the study. Short-acting inhaled b2-agonists were
permitted soon after each test when required. Due
to ethical considerations and the recommendations
of current guidelines for the hospital management
of exacerbations of COPD,16 all patients were
treated with oral prednisolone 30-mg daily and
supplemental oxygen, when required, soon after
the end of each session. All patients also received a
treatment with an oral antibiotic (co-amoxiclav or
levofloxacin). Patients were asked not to consume
cola drinks, coffee or tea and not to smoke in the
hours before and during the investigation.
After a rest of 15min while the patient was
breathing room air, an arterial catheter was placed
in the brachial artery. Samples of arterial blood
(5ml) were removed for measurement of PaO2,
PaCO2, and pH with a blood gas analyzer. The
machine output was checked daily with a standard
test sample. During the study period, the SD values
were 70.6mmHg for PaO2, 70.5mmHg for PaCO2,
and70.011 for pH). Blood gas analysis was repeated
at 10, 20, 30, 60, 90, and 120min, always on room
air. In the third group of patients, spirometry was
performed at the same time intervals.
The change in PaO2 after each treatment, from
the baseline obtained on that day, was the primary
outcome variable. The magnitude of changes in
blood-gas tensions and spirometric values at each
analysis time was compared among treatments.
The paired t-test and analysis of variance (ANOVA)
were used to determine the significance of differ-
ences among agents. Statistical significance was
accepted at Po0:05.Results
The changes in PaO2 values following formoterol
administration in the first step of the study (Fig. 1)
showed a small but statistically significant decrease
from baseline after each dose. The magnitude of
decline in PaO2 did not significantly increase with
the highest dose, the greatest mean change being
4.0mmHg (95% CI: 6.7 to 1.3) at 30min after
formoterol 9 mg, and 5.5mmHg (95% CI: 7.9 to
3.1) at 60min after formoterol 18 mg. Moreover,
at 120min the magnitude of decline was2.2mmHg (95% CI: 5.0 to 0.6) after formoterol
9 mg and 4.0mmHg (95% CI: 6.8 to 1.2) after
formoterol 18 mg. Both formoterol 9 and 18 mg
induced a decrease in PaCO2 (Fig. 1), but the
effect was higher (2.9mmHg; 95% CI: 5.8 to 0.1,
at 60min) after formoterol 9 mg than (1.4mmHg;
95% CI: 3.0 to 0.2, at 10min) after formoterol
18 mg.
In the second group of patients, formoterol 9 mg
alone again induced a significant decrease in PaO2,
with the greatest mean change being 5.3mmHg
(95% CI: 8.9 to 1.7) at 60min, and a fall of
2.4mmHg (95% CI: 6.1 to 1.3) at 120min
(Fig. 2). However, the simultaneous administration
of budesonide 320 mg significantly reduced the
acute effect of formoterol on PaO2, the greatest
mean change being 1.7mmHg (95% CI: 3.4 to
0.0) at 20min (Fig. 2). Also, in this group of
patients, the administration of formoterol 9 mg
induced a decrease in PaCO2 with a maximum fall
(5.3mmHg; 95% CI: 9.0 to 1.6) recorded
after 20min (Fig. 2). The inhalation of the fixed
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Figure 2 Mean changes (7SE) in PaO2 and PaCO2 with
time after administration of formoterol (F) 9mg and
formoterol (F) 9 mg+budesonide (B) 320 mg via Turbuhaler
(step 2). Po0:05, Po0:01 vs baseline.
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Figure 3 Mean changes (7SE) in FEV1 and PaO2 with time
after administration of formoterol (F) 9mg and formoter-
ol (F) 9 mg+budesonide (B) 320 mg via Turbuhaler (step 3).
Po0:05, Po0:01, Po0:001 vs. baseline.
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reduced the size of this decrease (2.1mmHg;
95% CI: 4.1 to 0.0) at 30min.
As expected, formoterol 9 mg caused a fall in
PaO2 also in the third group of patients, with a
maximum decrease (5.7mmHg; 95% CI: 8.5 to
2.9) observed after 60min (Fig. 3). Again, the
simultaneous administration of budesonide 320 mg
reduced the acute effect of formoterol on PaO2
(1.7mmHg (95% CI: 3.7 to 0.3, at 20min). The
mean increases in FEV1 were always higher after
formoterol/budesonide than formoterol alone, and
only the combination therapy induced a significant
improvement over baseline at each explored time
point (Fig. 3).Discussion
In this study, formoterol, taken in recommended
dosages, resulted in a significant decline in PaO2that could be attributed to its pulmonary vasodi-
lator effects mediated via b2-adrenoceptors on
vascular smooth muscle. However, the addition of
budesonide reduced the acute effect of formoterol
on blood-gas tensions. These findings suggest that
the use of formoterol in the treatment of acute
exacerbations of COPD must always be cautious,
but there is room for exploring the use of higher
than customary doses of the combination formoter-
ol/budesonide in this pathological condition.
It is not easy to justify why the addition of
budesonide can reduce the acute effect of for-
moterol on blood gases. Increased blood flow to
increased ventilated lung regions and, thus, de-
creased ventilation–perfusion inequality might be a
possibility. This explanation is based on the fact
that formoterol induces a stimulation of pulmonary
vessels in areas that are rapidly opened due to the
facilitated broncholytic action of formoterol driven
by budesonide. In other words, we are suggesting
the opening of vessels in lung areas that are better
ARTICLE IN PRESS
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activity of the combination formoterol/budesonide
when compared to formoterol alone.
Actually, results of the present study have
confirmed and enlarged our previous documenta-
tion that the addition of budesonide to formoterol
amplifies the fast onset of action of formoterol on
airways, at least when the two drugs are adminis-
tered via a single inhaler.12 In particular, in the
present study, we have observed that this action is
possible even in patients suffering from acute
exacerbation of COPD.
Another possible explanation of the interference
of budesonide on the acute effect of formoterol on
blood gases is linked to the documented potential
of inhaled corticosteroids to exert an acute reduc-
tion of bronchial blood flow.17 Apparently, budeso-
nide is particularly active in reducing airway blood
flow.18 This effect might be explained by the
capacity of corticosteroids to interfere with nora-
drenaline uptake by smooth-muscle cells of human
bronchial arteries (extraneural uptake: uptake2).
This could consequently increase noradrenaline
concentration at a-adrenergic receptor sites of
the bronchial vascular smooth muscle.19 The
pulmonary vasculature expresses a-adrenoceptors.
The stimulation of these receptors induces pro-
duces vasoconstriction.20 This effect might divert
blood flow away from poorly ventilated alveoli to
the regions that are better ventilated, thereby
optimising ventilation/perfusion ratio matching,
and maintaining an adequate systemic PaO2.
20
It is likely that the facilitating action of budeso-
nide was due to a nongenomic effect. In fact, it
appeared almost instantaneously, and certainly
within a time frame that precluded significant
modifications of gene expression. Although many
nongenomic effects might also occur over a time
scale that might include genomic action,21 one of
the main characteristics supporting a genomic-
mediated steroid effect is the prolonged period
between the initial application of the agent and the
onset of the cellular response.22 For most steroids,
including glucocorticoids, the typical latency time
ranges from 30min to several hours or even days.23
Recent evidence indicates that corticosteroids can
act at the membrane to exert rapid nongenomic
effects.24 The documentation that inhaled budeso-
nide inhibited allergic reaction within 10min in
guinea pigs sensitised with ovalbumin and chal-
lenged with the same antigen given by aerosol,
which would preclude genomic-mediated responses
that normally takes several hours to occur, is really
intriguing.25 Equally intriguing is the documenta-
tion that uptake2 is inhibited by steroid hormones
through a nongenomic action.19In conclusion, our results suggest that when
treating patients suffering from acute exacerbation
of COPD with formoterol, it is prudent to check
their arterial blood gases because this bronchodi-
lator can worsen pretreatment hypoxemia. How-
ever, combined administration of formoterol and
budesonide reduces the potential for acute effects
of formoterol on blood-gas tensions. This finding
indicates the possibility of exploring the impact of
high than customary doses of formoterol/budeso-
nide combination in the treatment of this patholo-
gic condition.Acknowledgements
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